Rada will consider the petition on the legalization of marijuana

Рада рассмотрит петицию о легализации марихуаны

The Parliament is called to legalize the use of marijuana for medical purposes

A petition on the website of the Parliament gathered 25 thousand signatures in less than a month and a half.

Petition to legalize the use of cannabis for medical and scientific purposes scored 25 thousand signatures on the website of the Verkhovna Rada.

The authors of the petition demand a law to regulate the access of patients to drugs from cannabis to treat chronic pain, epilepsy, anorexia, post-traumatic stress syndrome, immune system diseases, arthritis and rheumatism, asthma, Alzheimer’s disease, Parkinson’s disease, Huntington’s chorea, herpes, ulcers, weight loss during AIDS, diabetic neuropathy, different forms of sclerosis, and so on.

MPs urged changes in the law to create appropriate conditions for the full use of cannabis for medical and research activities, including for the purpose of development, clinical trials, state registration of effective drugs or treatment protocols that involve the use of products containing cannabinoids.

In addition, Parliament urged to allow patients to buy, store, and transport products with the content of cannabinoids with the aim of application in medical purposes and without the purpose of sale.

“We need to settle the law that denies scientific truth. Required to alleviate the suffering of patients and to protect the right of citizens to decent life and access to modern and effective treatment,” reads the petition text.

According to the law On citizens e-petition addressed to BP, needs to earn at least 25 thousand signatures within three months from the date of promulgation of treatment. After that, on the Council website within three working days to publish the data on the beginning of the consideration of e-petitions.

The petition was registered on 30 January 2019. The initiative was supported by the Minister of health Ulyana Suprun.


News from the Reporter.net Telegram. Subscribe to our channel https://t.me/korrespondentnet